Adrian M. Di Bisceglie, MD, FACP   has received grant/research support from Abbott Laboratories, Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, Hoffmann-La Roche, Ltd, Gilead Sciences, Inc, GlobeImmune, Inc, Idenix Pharmaceuticals, Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc, Tibotec Pharmaceuticals, Ltd, Transgene Biotek Ltd, and Vertex Pharmaceuticals Inc; is a consultant for and/or on the advisory board of Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, GlobeImmune, Inc, Hoffmann-La Roche, Ltd, Merck & Co., Inc, Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc, Salix Pharmaceuticals, Inc, Tibotec Pharmaceuticals, Ltd, and Vertex Pharmaceuticals Incorporated; and is a member of the data safety monitoring boards of Anadys Pharmaceuticals, Inc, and Bayer AG

Robert G. Gish, MD   has received grant/research support through an institutional fund under contract to the University of California San Diego research program from Astellas Pharma Inc/OSI Pharmaceuticals, Inc, Bayer/Onyx, Bristol-Myers Squibb, Genentech/Hoffmann-La Roche Ltd, Gilead Sciences, Inc, Merck & Co, Inc, and Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc; is a consultant for Abbott Laboratories, Astellas Pharma Inc/OSI Pharmaceuticals, Inc, Bayer AG, Bristol-Myers Squibb, DURECT Corporation, Genentech/Hoffmann-La Roche Ltd, Gilead Sciences, Inc, GlobeImmune, Inc, HepaHope, Inc, Kadmon Corporation, LLC, Merck & Co, Inc, Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc, Schering-Plough Corporation, and VitalTherapies [funds directed to a UCSD SPF fund for research and education]; is on the speakers bureau of Bayer Corporation, Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Hoffmann-La Roche, Ltd, Merck & Co, Inc/Schering-Plough Corporation, Onyx Pharmaceuticals, Inc, Roche Pharmaceuticals, Salix Pharmaceuticals, Inc, SciClone Pharmaceuticals, and Three Rivers Pharmaceuticals [funds, except for Merck and Vertex, directed to a UCSD SPF fund for research and education]; is a major stock shareholder of HepaHope, Inc, and a minor stock shareholder of Kinex Pharmaceuticals.

Kris V. Kowdley, MD   has received grant/research support from Abbott Laboratories, Boehringer Ingelheim, Bristol-Myers Squibb, Conatus Pharmaceuticals, Intercept Pharmaceuticals Inc, Merck & Co, Inc, Mochida Pharmaceutical Co, Ltd, and Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc; and has received consulting fees from Abbott Laboratories, Merck & Co, Inc, Novartis Pharmaceuticals Corporation, Pharmasset, a wholly-owned subsidiary of Gilead Sciences, Inc, and Vertex Pharmaceuticals Incorporated.

Helen S. Te, MD   has disclosed no significant relationships.

Hashem B. El-Serag, MD, MPH   has received grant/research support from Abbott Laboratories.

Albert D. Min, MD   has received grant/research support, honoraria, and fees for non-CME services from Bristol-Myers Squibb, Gilead Sciences, Inc, Salix Pharmaceuticals, Inc, and Vertex Pharmaceuticals Incorporated; and has received consulting fees and/or is on the advisory board of Bayer Corporation, Gilead Sciences, Inc, and Vertex Pharmaceuticals Incorporated.